What is Kurin?
Kurin, Inc. is at the forefront of developing innovative blood culture collection solutions designed to enhance patient safety and diagnostic accuracy. Their flagship product, the Kurin® blood culture collection set, incorporates the proprietary Kurin Lock® technology. This system is clinically validated and FDA-indicated to substantially reduce the incidence of skin contaminants in blood samples without requiring changes to established clinical workflows. By minimizing contamination, Kurin aims to improve patient outcomes and reduce the overall economic burden on healthcare systems associated with misdiagnoses and prolonged treatment for bloodstream infections.
How much funding has Kurin raised?
Kurin has raised a total of $2.7M across 2 funding rounds:
Private Equity
$2.3M
Debt
$350K
Private Equity (2016): $2.3M, investors not publicly disclosed
Debt (2020): $350K led by PPP
What's next for Kurin?
The recent major strategic investment signals a pivotal phase for Kurin, likely enabling the company to scale its operations, expand its market reach, and further invest in research and development. This infusion of capital is expected to accelerate the adoption of their contamination-reducing technology across a broader range of healthcare institutions. Kurin's focus on improving the reliability of blood culture testing positions it for continued growth as healthcare providers increasingly prioritize efficient and accurate diagnostic tools to combat infectious diseases.
See full Kurin company page
